Displaying drugs 7951 - 7975 of 8039 in total
EHT 0202
EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Investigational
Dovitinib
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I...
Investigational
Caldaret
Investigational
LGD-1550
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
Labetuzumab
Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Investigational
Oregovomab
Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Investigational
CX516
Investigational
Tipapkinogene sovacivec
Investigational
MAS825
Investigational
DOTMP HO-166
DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy...
Investigational
4-O-Demethylpenclomedine
Investigational
Pegdinetanib
CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT-322 blocks all known ligands for VEGFR-2.
Investigational
Fiboflapon
Investigational
Lucatumumab
Investigational
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Meplazumab
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Investigational
Dihydroquinidine barbiturate
Experimental
Tridolgosir
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Experimental
BNC105
Investigational
Tucidinostat
Investigational
Endostatin
Investigational
Saredutant
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Recombinant Bacterial ACE2 Receptors-like Enzyme
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Investigational
APD668
APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also avoid hypoglycemia.
Investigational
Displaying drugs 7951 - 7975 of 8039 in total